Draft guidance from UK's NICE recommends Celgene and Janssen Cilag multiple myeloma drugs; Sanofi-Aventis' Multaq approved for AF

27 August 2010

In what has been a busy week for the agency, draft guidance published yesterday (26 August), by the UK National Health Service watchdog the Institute for Health and Clinical Excellence (NICE) has recommended two treatments for multiple myeloma and reversed an earlier negative decision on .on an atrial fibrillation product.

The NICE stated that US drugmaker Celgene (Nasdaq: CELG) Thalidomide (thalidomide) in combination with an alkylating agent and a corticosteroid is recommended for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate.

Additionally, it said that US drug major Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag's Velcade (bortezomib) in combination with an alkylating agent and a corticosteroid is recommended as a treatment option if the person is unable to tolerate or has contraindications to thalidomide.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK